GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Asset Turnover

Journey Medical (Journey Medical) Asset Turnover : 0.18 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Journey Medical's Revenue for the three months ended in Mar. 2024 was $13.03 Mil. Journey Medical's Total Assets for the quarter that ended in Mar. 2024 was $71.71 Mil. Therefore, Journey Medical's Asset Turnover for the quarter that ended in Mar. 2024 was 0.18.

Asset Turnover is linked to ROE % through Du Pont Formula. Journey Medical's annualized ROE % for the quarter that ended in Mar. 2024 was -250.85%. It is also linked to ROA % through Du Pont Formula. Journey Medical's annualized ROA % for the quarter that ended in Mar. 2024 was -58.25%.


Journey Medical Asset Turnover Historical Data

The historical data trend for Journey Medical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical Asset Turnover Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
1.03 1.04 0.85 0.73 0.87

Journey Medical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.21 0.51 0.21 0.18

Competitive Comparison of Journey Medical's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Journey Medical's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Journey Medical's Asset Turnover falls into.



Journey Medical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Journey Medical's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=79.181/( (105.16+76.849)/ 2 )
=79.181/91.0045
=0.87

Journey Medical's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=13.03/( (76.849+66.571)/ 2 )
=13.03/71.71
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Journey Medical  (NAS:DERM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Journey Medical's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-41.768/16.6505
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-41.768 / 52.12)*(52.12 / 71.71)*(71.71/ 16.6505)
=Net Margin %*Asset Turnover*Equity Multiplier
=-80.14 %*0.7268*4.3068
=ROA %*Equity Multiplier
=-58.25 %*4.3068
=-250.85 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Journey Medical's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-41.768/71.71
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-41.768 / 52.12)*(52.12 / 71.71)
=Net Margin %*Asset Turnover
=-80.14 %*0.7268
=-58.25 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Journey Medical Asset Turnover Related Terms

Thank you for viewing the detailed overview of Journey Medical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Journey Medical (Journey Medical) Business Description

Traded in Other Exchanges
N/A
Address
9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.
Executives
Jeffrey Paley director C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith director C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Claude Maraoui director, officer: President & CEO C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch officer: Interim CFO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Journey Medical (Journey Medical) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Journey Medical Corp Shares

By GuruFocus Research GuruFocus Editor 05-19-2023